title: [The use of intermediate dose cytosine arabinoside (ID Ara-C) in the treatment of relapsing or refractory cases of acute myelogenous leukemia].
authors.forename: F
authors.initials: F
authors.lastname: Kawano
authors.forename: Y
authors.initials: Y
authors.lastname: Tejima
authors.forename: H
authors.initials: H
authors.lastname: Tajima
authors.forename: S Y
authors.initials: SY
authors.lastname: Lee
authors.forename: A
authors.initials: A
authors.lastname: Shiozaki
authors.forename: R
authors.initials: R
authors.lastname: Nakai
authors.forename: M
authors.initials: M
authors.lastname: Chyosa
authors.forename: T
authors.initials: T
authors.lastname: Sawada
authors.forename: Y
authors.initials: Y
authors.lastname: Maeda
authors.forename: T
authors.initials: T
authors.lastname: Mizokuni
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage* / Q000627:therapeutic use; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D003561:Cytarabine; D014750:Vincristine; D004317:Doxorubicin